Sign up
Pharma Capital

IXICO unveils appointment of UK Biobank finance director Grant Nash as its chief financial officer

The AIM-listed neuroscience data analytics company said Grant will join the company on 29 April 2019 and it is anticipated that he will join the board in due course
Handshake
Prior to his time with the UK Biobank, Grant spent 10 years with Evotec AG, latterly as senior vice president of finance

IXICO PLC (LON:IXI) has announced the appointment of Grant Nash, currently finance director of the UK Biobank - a national and international health research data resource - as the company's chief financial officer.

The AIM-listed neuroscience data analytics company said Grant will join the company on 29 April 2019 and it is anticipated that he will join the board in due course.

READ: IXICO parts with director Susan Lowther

It added that Grant has been finance director of the UK Biobank since 2014, where he was also responsible for the UK Biocentre, which provides biomedical sample processing and archiving logistics to large-scale research studies.

Prior to his time with the UK Biobank, Grant spent 10 years with Evotec AG, latterly as senior vice president of finance, where he was responsible for the finance, IT, procurement facilities and logistics functions.

IXICO said Conor Woolfson, who assumed the role of interim head of finance in December 2018 after the departure of Susan Lowther, will continue to perform these duties prior to Grant's appointment, at which time he will then continue in his role of group financial controller, reporting to Grant.

Giulio Cerroni, IXICO’s chief executive said: "We are at an exciting stage of the Company's development, and Grant's business experience in international commercial and large-scale research and development organisations will assist the Board and management team in delivering against our strategic objectives."

View full IXI profile View Profile
View All

Related Articles

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.